Keratosis pilaris

disease
On this page

Also known as KP

Summary

Keratosis pilaris (MONDO:0021036) is a disease with 1 cohort gene and 8 clinical trials.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 14
  • Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namekeratosis pilaris
Mondo IDMONDO:0021036
ICD-111614890502
NCITC124070
SNOMED CT5132005
UMLSC0263383
MedGen82664
Is cancer (heuristic)no

Also known as: KP

Data availability: 14 ClinVar variants.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorderkeratosis pilaris

Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome

Subtypes (1): keratosis pilaris atrophicans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

14 retrieved; paginated sample, class counts are floors:

12 benign, 1 pathogenic, 1 conflicting classifications of pathogenicity

ClinVarVariant (HGVS)GeneClassificationReview
132834NM_002332.3(LRP1):c.3734A>G (p.Lys1245Arg)LRP1Pathogenicno assertion criteria provided
930178NM_002332.3(LRP1):c.300C>T (p.Asp100=)LRP1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1222429NM_002332.3(LRP1):c.8574C>T (p.Cys2858=)LRP1Benigncriteria provided, multiple submitters, no conflicts
1226322NM_002332.3(LRP1):c.3546C>T (p.Cys1182=)LRP1Benigncriteria provided, multiple submitters, no conflicts
1236943NM_002332.3(LRP1):c.7278C>T (p.Ala2426=)LRP1Benigncriteria provided, multiple submitters, no conflicts
1252707NM_002332.3(LRP1):c.8893-7C>TLRP1Benigncriteria provided, multiple submitters, no conflicts
1253715NM_002332.3(LRP1):c.8925C>T (p.Asp2975=)LRP1Benigncriteria provided, multiple submitters, no conflicts
1271847NM_002332.3(LRP1):c.8997T>C (p.Thr2999=)LRP1Benigncriteria provided, multiple submitters, no conflicts
1272520NM_002332.3(LRP1):c.8699A>C (p.Gln2900Pro)LRP1Benigncriteria provided, multiple submitters, no conflicts
1280360NM_002332.3(LRP1):c.8702-5C>TLRP1Benigncriteria provided, multiple submitters, no conflicts
1282327NM_002332.3(LRP1):c.6842-22C>GLRP1Benigncriteria provided, multiple submitters, no conflicts
1285717NM_002332.3(LRP1):c.9282+11C>TLRP1Benigncriteria provided, multiple submitters, no conflicts
1297892NM_002332.3(LRP1):c.3793+25G>ALRP1Benigncriteria provided, multiple submitters, no conflicts
1300111NM_002332.3(LRP1):c.9783G>A (p.Thr3261=)LRP1Benigncriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
LRP1Orphanet:2340Keratosis follicularis spinulosa decalvans
LRP1Orphanet:79100Atrophoderma vermiculata

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
LRP1HGNC:6692ENSG00000123384Q07954Prolow-density lipoprotein receptor-related protein 1clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
LRP1Prolow-density lipoprotein receptor-related protein 1Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
LRP1Other/UnknownnoLDLR_classB_rpt, EGF-type_Asp/Asn_hydroxyl_site, EGF

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
ascending aorta1
descending thoracic aorta1
stromal cell of endometrium1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
LRP1293ubiquitousmarkerstromal cell of endometrium, descending thoracic aorta, ascending aorta

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
LRP12,662

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
LRP1Q079547

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 9. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Scavenging of heme from plasma1878.5×0.007LRP1
Binding and Uptake of Ligands by Scavenger Receptors1543.8×0.007LRP1
Metabolism of fat-soluble vitamins1380.7×0.007LRP1
Visual phototransduction1259.6×0.007LRP1
Retinoid metabolism and transport1248.3×0.007LRP1
Metabolism of vitamins and cofactors1116.5×0.013LRP1
Sensory Perception195.2×0.014LRP1
Vesicle-mediated transport134.8×0.032LRP1
Metabolism111.6×0.086LRP1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
positive regulation of transcytosis116852.0×0.001LRP1
positive regulation of lipid transport18426.0×0.001LRP1
positive regulation of reverse cholesterol transport18426.0×0.001LRP1
astrocyte activation involved in immune response14213.0×0.001LRP1
negative regulation of platelet-derived growth factor receptor-beta signaling pathway14213.0×0.001LRP1
regulation of extracellular matrix disassembly13370.4×0.001LRP1
positive regulation of lysosomal protein catabolic process13370.4×0.001LRP1
amyloid-beta clearance by transcytosis12407.4×0.002LRP1
amyloid-beta clearance by cellular catabolic process12106.5×0.002LRP1
positive regulation of amyloid-beta clearance12106.5×0.002LRP1
regulation of extracellular matrix organization11872.4×0.002LRP1
transcytosis11685.2×0.002LRP1
negative regulation of smooth muscle cell migration11532.0×0.002LRP1
enzyme-linked receptor protein signaling pathway11296.3×0.002LRP1
lipoprotein transport1991.3×0.002LRP1
amyloid-beta clearance1936.2×0.002LRP1
aorta morphogenesis1887.0×0.002LRP1
apoptotic cell clearance1887.0×0.002LRP1
positive regulation of endocytosis1802.5×0.002LRP1
lysosomal transport1702.2×0.002LRP1
positive regulation of cholesterol efflux1624.1×0.002LRP1
negative regulation of SMAD protein signal transduction1601.9×0.002LRP1
retinoid metabolic process1495.6×0.003LRP1
cellular response to amyloid-beta1391.9×0.004LRP1
negative regulation of Wnt signaling pathway1343.9×0.004LRP1
receptor internalization1324.1×0.004LRP1
positive regulation of protein localization to plasma membrane1271.8×0.004LRP1
phagocytosis1240.7×0.005LRP1
receptor-mediated endocytosis1221.7×0.005LRP1
transport across blood-brain barrier1179.3×0.006LRP1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
LRP100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1LRP1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
LRP10

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified6
PHASE42

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00944216PHASE4TERMINATEDEfficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study
NCT04797663PHASE4COMPLETEDLong-pulsed 1064 nm Nd-YAG Laser Versus TCA 20% in Treatment of Keratosis Pilaris
NCT07078461Not specifiedRECRUITINGInvestigating the Safety and Efficacy of the 1927-nm Thulium Laser in Keratosis Pilaris
NCT01281644Not specifiedCOMPLETEDTreatment of Keratosis Pilaris With 810 nm Diode Laser
NCT03243617Not specifiedCOMPLETEDCosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris
NCT05535517Not specifiedUNKNOWNDevelopment and Validation of an Investigator Global Assessment Score for Keratosis Pilaris
NCT05666011Not specifiedUNKNOWNLaser to Aid in Treatment of Keratosis Pilaris on Arms
NCT06032078Not specifiedUNKNOWNEvaluation of the Responsiveness of Investigator Global Assessment Score for Keratosis Pilaris